Cytokine profiling analysis
This invention relates to methods for predicting a prognosis of a patient with cancer in need of an anti-cancer treatment comprising measuring a cytokine score from a sample obtained from the patient. In some embodiments, the subject is administered an anti-cancer treatment, e.g., an anti-PD-1 antibody, following the cytokine score measurement. In some embodiments, the cancer is lung cancer.
1. A method of treating a human patient in need of an anti-cancer treatment comprising (i) determining a concentration level of one or more cytokines selected from the group consisting of MIG, IL-1RA, MMP-3, and any combination thereof and one or more cytokines selected from the group consisting of IL-8, FRTN, ICAM, VWF, MICA, IP-10, CRP, IL-18, IL-6, MIP1B, and any combination thereof; and (ii) administering to the patient an effective amount of an anti-PD-1 antibody or antigen-binding portion thereof (“anti-PD-1 antibody”) or an effective amount of an anti-PD-L1 antibody or antigen-binding portion thereof (“anti-PD-L1 antibody”).
2. The method of claim 1 , wherein the patient has lung cancer.
3. The method of claim 2 , wherein the lung cancer is non-small cell lung cancer.
4. The method of claim 1 , wherein the patient has a high concentration level of at least two cytokines selected from the group consisting of MIG, IL-1RA, and MMP-3.
5. The method of claim 1 , wherein the patient has a low concentration level of at least two cytokines selected from the group consisting of IL-8, FRTN, ICAM, VWF, MICA, IP-10, CRP, IL-18, IL-6, and MIP1B.
6. The method of claim 1 , wherein the anti-PD-1 antibody is nivolumab.
7. The method of claim 1 , wherein the anti-PD-L1 antibody is selected from BMS-936559, MPDL3280A, MEDI4736, and MSB0010718C.
8. The method of claim 1 , wherein the anti-PD-1 antibody is pembrolizumab.
9. The method of claim 1 , wherein the patient has a high concentration level of MIG, IL-1RA, and MMP-3.
10. The method of claim 1 , wherein
(i) a sample obtained from the patient has a high concentration level of the one or more cytokines selected from the group consisting of MIG, IL-1RA, MMP-3, and any combination thereof; and
(ii) a sample obtained from the patient has a low concentration level of one or more cytokines selected from the group consisting of IL-8, FRTN, ICAM, VWF, MICA, IP-10, CRP, IL-18, IL-6, MIP1B, and any combination thereof;
wherein the high concentration level and/or the low concentration level is determined by comparing the concentration level of the cytokine in the sample obtained from the patient to an average concentration level of the cytokine in a population of patients.